Fangchinoline protects against bone loss in OVX mice via inhibiting osteoclast formation, bone resorption and RANKL-induced signaling

International Journal of Biological Sciences
2020.0

Abstract

Osteoporosis is a disease characterized by abnormally increased formation and function of osteoclasts. Anti-RANKL treatment using natural medicine is a potential therapy for osteoporosis. Here, we studied the effect of fangchinoline, which is extracted from the root of Stephania tetrandra S. Moore, on osteoclast formation and function. We found that fangchinoline inhibited osteoclastogenesis at doses of 0.5 and 1 microM. In addition, we also examined the mechanism of the inhibitory effect of fangchinoline on osteoclasts. We found that fangchinoline down regulated NFATc1 activity and expression. However, fangchinoline did not affect IkappaBalpha degradation and MAPK pathways. In addition, we also found that fangchinoline could protect against bone loss in OVX mice. Taken together, fangchinoline may be a potential compound for osteoporosis. CI - (c) The author(s).

Knowledge Graph

Similar Paper

Fangchinoline protects against bone loss in OVX mice via inhibiting osteoclast formation, bone resorption and RANKL-induced signaling
International Journal of Biological Sciences 2020.0
Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
Frontiers in Pharmacology 2020.0
Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
Frontiers in Endocrinology 2021.0
Aloperine improves osteoporosis in ovariectomized mice by inhibiting RANKL-induced NF-κB, ERK and JNK approaches
International Immunopharmacology 2021.0
Formononetin Attenuates Osteoclastogenesis via Suppressing the RANKL-Induced Activation of NF-κB, c-Fos, and Nuclear Factor of Activated T-Cells Cytoplasmic 1 Signaling Pathway
Journal of Natural Products 2014.0
<scp>l</scp>‐tetrahydropalmatine suppresses osteoclastogenesis in vivo and in vitro via blocking RANK‐TRAF6 interactions and inhibiting NF‐κB and MAPK pathways
Journal of Cellular and Molecular Medicine 2020.0
Isoliensinine Suppresses Osteoclast Formation Through NF-κB Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss
Frontiers in Pharmacology 2022.0
Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
Frontiers in Pharmacology 2022.0
A Novel RANKL‐Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF‐κB Signal Pathway and Reducing Reactive Oxygen Species
Oxidative Medicine and Cellular Longevity 2022.0
Securinine suppresses osteoclastogenesis and ameliorates inflammatory bone loss
Phytotherapy Research 2020.0